Interferon gamma explained

Symbol:IFN gamma
Interferon gamma
Pfam:PF00714
Pfam Clan:CL0053
Interpro:IPR002069
Scop:1rfb
Verifiedfields:changed
Verifiedrevid:458270952
Iupac Name:Human interferon gamma-1b
Tradename:Actimmune
Cas Number:98059-61-1
Unii:21K6M2I7AG
Atc Prefix:L03
Atc Suffix:AB03
Drugbank:DB00033
Chembl:1201564
Chemspiderid:none
C:761
H:1206
N:214
O:225
S:6

Interferon gamma (IFNG or IFN-γ) is a dimerized soluble cytokine that is the only member of the type II class of interferons.[1] The existence of this interferon, which early in its history was known as immune interferon, was described by E. F. Wheelock as a product of human leukocytes stimulated with phytohemagglutinin, and by others as a product of antigen-stimulated lymphocytes.[2] It was also shown to be produced in human lymphocytes.[3] or tuberculin-sensitized mouse peritoneal lymphocytes[4] challenged with Mantoux test (PPD); the resulting supernatants were shown to inhibit growth of vesicular stomatitis virus. Those reports also contained the basic observation underlying the now widely employed interferon gamma release assay used to test for tuberculosis. In humans, the IFNG protein is encoded by the IFNG gene.[5] [6]

Through cell signaling, interferon gamma plays a role in regulating the immune response of its target cell. A key signaling pathway that is activated by type II IFN is the JAK-STAT signaling pathway. IFNG plays an important role in both innate and adaptive immunity. Type II IFN is primarily secreted by CD4+ T helper 1 (Th1) cells, natural killer (NK) cells, and CD8+ cytotoxic T cells. The expression of type II IFN is upregulated and downregulated by cytokines. By activating signaling pathways in cells such as macrophages, B cells, and CD8+ cytotoxic T cells, it is able to promote inflammation, antiviral or antibacterial activity, and cell proliferation and differentiation. Type II IFN is serologically different from interferon type 1, binds to different receptors, and is encoded by a separate chromosomal locus.[7] Type II IFN has played a role in the development of cancer immunotherapy treatments due to its ability to prevent tumor growth.

Function

IFNG, or type II interferon, is a cytokine that is critical for innate and adaptive immunity against viral, some bacterial and protozoan infections. IFNG is an important activator of macrophages and inducer of major histocompatibility complex class II molecule expression. Aberrant IFNG expression is associated with a number of autoinflammatory and autoimmune diseases. The importance of IFNG in the immune system stems in part from its ability to inhibit viral replication directly, and most importantly from its immunostimulatory and immunomodulatory effects. IFNG is produced predominantly by natural killer cells (NK) and natural killer T cells (NKT) as part of the innate immune response, and by CD4 Th1 and CD8 cytotoxic T lymphocyte (CTL) effector T cells once antigen-specific immunity develops[8] [9] as part of the adaptive immune response. IFNG is also produced by non-cytotoxic innate lymphoid cells (ILC), a family of immune cells first discovered in the early 2010s.[10]

The primary cells that secrete type II IFN are CD4+ T helper 1 (Th1) cells, natural killer (NK) cells, and CD8+ cytotoxic T cells. It can also be secreted by antigen presenting cells (APCs) such as dendritic cells (DCs), macrophages (MΦs), and B cells to a lesser degree. Type II IFN expression is upregulated by the production of interleukin cytokines, such as IL-12, IL-15, IL-18, as well as type I interferons (IFN-α and IFN-β).[11] Meanwhile, IL-4, IL-10, transforming growth factor-beta (TGF-β) and glucocorticoids are known to downregulate type II IFN expression.[12]

Type II IFN is a cytokine, meaning it functions by signaling to other cells in the immune system and influencing their immune response. There are many immune cells type II IFN acts on. Some of its main functions are to induce IgG isotype switching in B cells; upregulate major histocompatibility complex (MHC) class II expression on APCs; induce CD8+ cytotoxic T cell differentiation, activation, and proliferation; and activate macrophages. In macrophages, type II IFN stimulates IL-12 expression. IL-12 in turn promotes the secretion of IFNG by NK cells and Th1 cells, and it signals naive T helper cells (Th0) to differentiate into Th1 cells.[13]

Structure

The IFNG monomer consists of a core of six α-helices and an extended unfolded sequence in the C-terminal region.[14] [15] This is shown in the structural models below. The α-helices in the core of the structure are numbered 1 to 6.

The biologically active dimer is formed by anti-parallel inter-locking of the two monomers as shown below. In the cartoon model, one monomer is shown in red, the other in blue.

Receptor binding

See also: Interferon-gamma receptor. Cellular responses to IFNG are activated through its interaction with a heterodimeric receptor consisting of Interferon gamma receptor 1 (IFNGR1) and Interferon gamma receptor 2 (IFNGR2). IFN-γ binding to the receptor activates the JAK-STAT pathway. Activation of the JAK-STAT pathway induces upregulation of interferon-stimulated genes (ISGs), including MHC II.[16] IFNG also binds to the glycosaminoglycan heparan sulfate (HS) at the cell surface. However, in contrast to many other heparan sulfate binding proteins, where binding promotes biological activity, the binding of IFNG to HS inhibits its biological activity.[17]

The structural models shown in figures 1-3 for IFNG[15] are all shortened at their C-termini by 17 amino acids. Full length IFNG is 143 amino acids long, the models are 126 amino acids long. Affinity for heparan sulfate resides solely within the deleted sequence of 17 amino acids.[18] Within this sequence of 17 amino acids lie two clusters of basic amino acids termed D1 and D2, respectively. Heparan sulfate interacts with both of these clusters.[19] In the absence of heparan sulfate the presence of the D1 sequence increases the rate at which IFNG-receptor complexes form.[17] Interactions between the D1 cluster of amino acids and the receptor may be the first step in complex formation. By binding to D1 HS may compete with the receptor and prevent active receptor complexes from forming.

The biological significance of heparan sulfates interaction with IFNG is unclear; however, binding of the D1 cluster to HS may protect it from proteolytic cleavage.[19]

Signaling

IFNG binds to the type II cell-surface receptor, also known as the IFN gamma receptor (IFNGR) which is part of the class II cytokine receptor family. The IFNGR is composed of two subunits: the IFNGR1 and IFNGR2. IFNGR1 is associated with JAK1 and IFNGR2 is associated with JAK2. Upon IFNG binding the receptor, IFNGR1 and IFNGR2 undergo conformational changes that result in the autophosphorylation and activation of JAK1 and JAK2. This leads to a signaling cascade and eventual transcription of target genes.[20] The expression of 236 different genes has been linked to type II IFN-mediated signaling. The proteins expressed by type II IFN-mediated signaling are primarily involved in promoting inflammatory immune responses and regulating other cell-mediated immune responses, such as apoptosis, intracellular IgG trafficking, cytokine signaling and production, hematopoiesis, and cell proliferation and differentiation.

JAK-STAT pathway

One key pathway triggered by IFNG binding IFNGRs is the Janus Kinase and Signal Transducer and Activator of Transcription pathway, more commonly referred to as the JAK-STAT pathway. In the JAK-STAT pathway, activated JAK1 and JAK2 proteins regulate the phosphorylation of tyrosine in STAT1 transcription factors. The tyrosines are phosphorylated at a very specific location, allowing activated STAT1 proteins to interact with each other come together to form STAT1-STAT1 homodimers. The STAT1-STAT1 homodimers can then enter the cell nucleus. They then initiate transcription by binding to gamma interferon activation site (GAS) elements, which are located in the promoter region of Interferon-stimulated genes (ISGs) that express for antiviral effector proteins, as well as positive and negative regulators of type II IFN signaling pathways.[21] The JAK proteins also lead to the activation of phosphatidylinositol 3-kinase (PI3K). PI3K leads to the activation of protein kinase C delta type (PKC-δ) which phosphorylates the amino acid serine in STAT1 transcription factors. The phosphorylation of the serine in STAT1-STAT1 homodimers are essential for the full transcription process to occur.

Other signaling pathways

Other signaling pathways that are triggered by IFNG are the mTOR signaling pathway, the MAPK signaling pathway, and the PI3K/AKT signaling pathway.

Biological activity

IFNG is secreted by T helper cells (specifically, Th1 cells), cytotoxic T cells (TC cells), macrophages, mucosal epithelial cells and NK cells. IFNG is both an important autocrine signal for professional APCs in early innate immune response, and an important paracrine signal in adaptive immune response. The expression of IFNG is induced by the cytokines IL-12, IL-15, IL-18, and type I IFN.[22] IFNG is the only Type II interferon and it is serologically distinct from Type I interferons; it is acid-labile, while the type I variants are acid-stable.

IFNG has antiviral, immunoregulatory, and anti-tumor properties.[23] It alters transcription in up to 30 genes producing a variety of physiological and cellular responses. Among the effects are:

IFNG is the primary cytokine that defines Th1 cells: Th1 cells secrete IFNG, which in turn causes more undifferentiated CD4+ cells (Th0 cells) to differentiate into Th1 cells, [27] representing a positive feedback loop—while suppressing Th2 cell differentiation. (Equivalent defining cytokines for other cells include IL-4 for Th2 cells and IL-17 for Th17 cells.)

NK cells and CD8+ cytotoxic T cells also produce IFNG. IFNG suppresses osteoclast formation by rapidly degrading the RANK adaptor protein TRAF6 in the RANK-RANKL signaling pathway, which otherwise stimulates the production of NF-κB.

Activity in granuloma formation

A granuloma is the body's way of dealing with a substance it cannot remove or sterilize. Infectious causes of granulomas (infections are typically the most common cause of granulomas) include tuberculosis, leprosy, histoplasmosis, cryptococcosis, coccidioidomycosis, blastomycosis, and toxoplasmosis. Examples of non-infectious granulomatous diseases are sarcoidosis, Crohn's disease, berylliosis, giant-cell arteritis, granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis, pulmonary rheumatoid nodules, and aspiration of food and other particulate material into the lung.[28] The infectious pathophysiology of granulomas is discussed primarily here.

The key association between IFNG and granulomas is that IFNG activates macrophages so that they become more powerful in killing intracellular organisms.[29] Activation of macrophages by IFNG from Th1 helper cells in mycobacterial infections allows the macrophages to overcome the inhibition of phagolysosome maturation caused by mycobacteria (to stay alive inside macrophages).[30] [31] The first steps in IFNG-induced granuloma formation are activation of Th1 helper cells by macrophages releasing IL-1 and IL-12 in the presence of intracellular pathogens, and presentation of antigens from those pathogens. Next the Th1 helper cells aggregate around the macrophages and release IFNG, which activates the macrophages. Further activation of macrophages causes a cycle of further killing of intracellular bacteria, and further presentation of antigens to Th1 helper cells with further release of IFNG. Finally, macrophages surround the Th1 helper cells and become fibroblast-like cells walling off the infection.

Activity during pregnancy

Uterine natural killer cells (NKs) secrete high levels of chemoattractants, such as IFNG in mice. IFNG dilates and thins the walls of maternal spiral arteries to enhance blood flow to the implantation site. This remodeling aids in the development of the placenta as it invades the uterus in its quest for nutrients. IFNG knockout mice fail to initiate normal pregnancy-induced modification of decidual arteries. These models display abnormally low amounts of cells or necrosis of decidua.[32]

In humans, elevated levels of IFN gamma have been associated with increased risk of miscarriage. Correlation studies have observed high IFNG levels in women with a history of spontaneous miscarriage, when compared to women with no history of spontaneous miscarriage.[33] Additionally, low-IFNG levels are associated with women who successfully carry to term. It is possible that IFNG is cytotoxic to trophoblasts, which leads to miscarriage.[34] However, causal research on the relationship between IFNG and miscarriage has not been performed due to ethical constraints.

Production

Recombinant human IFNG, as an expensive biopharmaceutical, has been expressed in different expression systems including prokaryotic, protozoan, fungal (yeasts), plant, insect and mammalian cells. Human IFNG is commonly expressed in Escherichia coli, marketed as ACTIMMUNE®, however, the resulting product of the prokaryotic expression system is not glycosylated with a short half-life in the bloodstream after injection; the purification process from bacterial expression system is also very costly. Other expression systems like Pichia pastoris did not show satisfactory results in terms of yields.[35] [36]

Therapeutic use

Interferon gamma 1b is approved by the U.S. Food and Drug Administration to treat chronic granulomatous disease[37] (CGD) and osteopetrosis.[38] The mechanism by which IFNG benefits CGD is via enhancing the efficacy of neutrophils against catalase-positive bacteria by correcting patients' oxidative metabolism.[39]

It was not approved to treat idiopathic pulmonary fibrosis (IPF). In 2002, the manufacturer InterMune issued a press release saying that phase III data demonstrated survival benefit in IPF and reduced mortality by 70% in patients with mild to moderate disease. The U.S. Department of Justice charged that the release contained false and misleading statements. InterMune's chief executive, Scott Harkonen, was accused of manipulating the trial data, was convicted in 2009 of wire fraud, and was sentenced to fines and community service. Harkonen appealed his conviction to the U.S. Court of Appeals for the Ninth Circuit, and lost.[40] Harkonen was granted a full pardon on January 20, 2021.[41]

Preliminary research on the role of IFNG in treating Friedreich's ataxia (FA) conducted by Children's Hospital of Philadelphia has found no beneficial effects in short-term (< 6-months) treatment.[42] [43] [44] However, researchers in Turkey have discovered significant improvements in patients' gait and stance after 6 months of treatment.[45]

Although not officially approved, Interferon gamma has also been shown to be effective in treating patients with moderate to severe atopic dermatitis.[46] [47] [48] Specifically, recombinant IFNG therapy has shown promise in patients with lowered IFNG expression, such as those with predisposition to herpes simplex virus, and pediatric patients.[49]

Potential use in immunotherapy

IFNG increases an anti-proliferative state in cancer cells, while upregulating MHC I and MHC II expression, which increases immunorecognition and removal of pathogenic cells.[50] IFNG also reduces metastasis in tumors by upregulating fibronectin, which negatively impacts tumor architecture.[51] Increased IFNG mRNA levels in tumors at diagnosis has been associated to better responses to immunotherapy.[52]

Cancer immunotherapy

The goal of cancer immunotherapy is to trigger an immune response by the patient's immune cells to attack and kill malignant (cancer-causing) tumor cells. Type II IFN deficiency has been linked to several types of cancer, including B-cell lymphoma and lung cancer. Furthermore, it has been found that in patients receiving the drug durvalumab to treat non-small cell lung carcinoma and transitional cell carcinoma had higher response rates to the drug, and the drug stunted the progression of both types of cancer for a longer duration of time. Thus, promoting the upregulation of type II IFN has been proven to be a crucial part in creating effective cancer immunotherapy treatments.[53]

IFNG is not approved yet for the treatment in any cancer immunotherapy. However, improved survival was observed when IFNG was administered to patients with bladder carcinoma and melanoma cancers. The most promising result was achieved in patients with stage 2 and 3 of ovarian carcinoma. On the contrary, it was stressed: "Interferon-γ secreted by CD8-positive lymphocytes upregulates PD-L1 on ovarian cancer cells and promotes tumour growth."[54] The in vitro study of IFNG in cancer cells is more extensive and results indicate anti-proliferative activity of IFNG leading to the growth inhibition or cell death, generally induced by apoptosis but sometimes by autophagy. In addition, it has been reported that mammalian glycosylation of recombinant human IFNG, expressed in HEK293, improves its therapeutic efficacy compared to the unglycosylated form that is expressed in E. coli.[55]

Involvement in antitumor immunity

Type II IFN enhances Th1 cell, cytotoxic T cell, and APC activities, which results in an enhanced immune response against the malignant tumor cells, leading to tumor cell apoptosis and necroptosis (cell death). Furthermore, Type II IFN suppresses the activity of regulatory T cells, which are responsible for silencing immune responses against pathogens, preventing the deactivation of the immune cells involved in the killing of the tumor cells. Type II IFN prevents tumor cell division by directly acting on the tumor cells, which results in increased expression of proteins that inhibit the tumor cells from continuing through the cell cycle (i.e., cell cycle arrest). Type II IFN can also prevent tumor growth by indirectly acting on endothelial cells lining the blood vessels close to the site of the tumor, cutting off blood flow to the tumor cells and thus the supply of necessary resources for tumor cell survival and proliferation.

Barriers

The importance of type II IFN in cancer immunotherapy has been acknowledged; current research is studying the effects of type II IFN on cancer, both as a solo form of treatment and as a form of treatment to be administered alongside other anticancer drugs. But type II IFN has not been approved by the Food and Drug Administration (FDA) to treat cancer, except for malignant osteoporosis. This is most likely due to the fact that while type II IFN is involved in antitumor immunity, some of its functions may enhance the progression of a cancer. When type II IFN acts on tumor cells, it may induce the expression of a transmembrane protein known as programmed death-ligand 1 (PDL1), which allows the tumor cells to evade an attack from immune cells. Type II IFN-mediated signaling may also promote angiogenesis (formation of new blood vessels to the tumor site) and tumor cell proliferation.

Interactions

Interferon gamma has been shown to interact with Interferon gamma receptor 1 and Interferon gamma receptor 2.[56] [57]

Diseases

Interferon gamma has been shown to be a crucial player in the immune response against some intracellular pathogens, including that of Chagas disease.[58] It has also been identified as having a role in seborrheic dermatitis.[59]

IFNG has a significant anti-viral effect in herpes simplex virus I (HSV) infection. IFNG compromises the microtubules that HSV relies upon for transport into an infected cell's nucleus, inhibiting the ability of HSV to replicate.[60] [61] Studies in mice on acyclovir resistant herpes have shown that IFNG treatment can significantly reduce herpes viral load. The mechanism by which IFNG inhibits herpes reproduction is independent of T-cells, which means that IFNG may be an effective treatment in individuals with low T-cells.[62] [63] [64]

Chlamydia infection is impacted by IFNG in host cells. In human epithelial cells, IFNG upregulates expression of indoleamine 2,3-dioxygenase, which in turn depletes tryptophan in hosts and impedes chlamydia's reproduction.[65] [66] Additionally, in rodent epithelial cells, IFNG upregulates a GTPase that inhibits chlamydial proliferation.[67] In both the human and rodent systems, chlamydia has evolved mechanisms to circumvent the negative effects of host cell behavior.[68]

Regulation

There is evidence that interferon-gamma expression is regulated by a pseudoknotted element in its 5' UTR.[69] There is also evidence that interferon-gamma is regulated either directly or indirectly by the microRNAs: miR-29.[70] Furthermore, there is evidence that interferon-gamma expression is regulated via GAPDH in T-cells. This interaction takes place in the 3'UTR, where binding of GAPDH prevents the translation of the mRNA sequence.[71]

Further reading

External links

Notes and References

  1. Gray PW, Goeddel DV . Structure of the human immune interferon gene . Nature . 298 . 5877 . 859–863 . August 1982 . 6180322 . 10.1038/298859a0 . 4275528 . 1982Natur.298..859G .
  2. Wheelock EF . Interferon-Like Virus-Inhibitor Induced in Human Leukocytes by Phytohemagglutinin . Science . 149 . 3681 . 310–311 . July 1965 . 17838106 . 10.1126/science.149.3681.310 . 1366348 . 1965Sci...149..310W .
  3. Green JA, Cooperband SR, Kibrick S . Immune specific induction of interferon production in cultures of human blood lymphocytes . Science . 164 . 3886 . 1415–1417 . June 1969 . 5783715 . 10.1126/science.164.3886.1415 . 32651832 . 1969Sci...164.1415G .
  4. Milstone LM, Waksman BH . Release of virus inhibitor from tuberculin-sensitized peritoneal cells stimulated by antigen . Journal of Immunology . 105 . 5 . 1068–1071 . November 1970 . 10.4049/jimmunol.105.5.1068 . 4321289 . 29861335 . free .
  5. Naylor SL, Sakaguchi AY, Shows TB, Law ML, Goeddel DV, Gray PW . Human immune interferon gene is located on chromosome 12 . The Journal of Experimental Medicine . 157 . 3 . 1020–1027 . March 1983 . 6403645 . 2186972 . 10.1084/jem.157.3.1020 .
  6. Web site: Entrez Gene: IFNGR2 .
  7. Lee AJ, Ashkar AA . The Dual Nature of Type I and Type II Interferons . Frontiers in Immunology . 9 . 2061 . 2018 . 30254639 . 6141705 . 10.3389/fimmu.2018.02061 . free .
  8. Web site: Entrez Gene: INFG .
  9. Book: Schoenborn JR, Wilson CB . Regulation of interferon-gamma during innate and adaptive immune responses . Advances in Immunology . 96 . 41–101 . 2007 . 17981204 . 10.1016/S0065-2776(07)96002-2 . Regulation of Interferon-γ During Innate and Adaptive Immune Responses . 978-0-12-373709-0 .
  10. Artis D, Spits H . The biology of innate lymphoid cells . Nature . 517 . 7534 . 293–301 . January 2015 . 25592534 . 10.1038/nature14189 . 4386692 . 2015Natur.517..293A .
  11. Castro F, Cardoso AP, Gonçalves RM, Serre K, Oliveira MJ . Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion . Frontiers in Immunology . 9 . 847 . 2018 . 29780381 . 5945880 . 10.3389/fimmu.2018.00847 . free .
  12. Bhat MY, Solanki HS, Advani J, Khan AA, Keshava Prasad TS, Gowda H, Thiyagarajan S, Chatterjee A . Comprehensive network map of interferon gamma signaling . Journal of Cell Communication and Signaling . 12 . 4 . 745–751 . December 2018 . 30191398 . 6235777 . 10.1007/s12079-018-0486-y .
  13. Tau G, Rothman P . Biologic functions of the IFN-gamma receptors . Allergy . 54 . 12 . 1233–1251 . December 1999 . 10688427 . 4154595 . 10.1034/j.1398-9995.1999.00099.x .
  14. Ealick SE, Cook WJ, Vijay-Kumar S, Carson M, Nagabhushan TL, Trotta PP, Bugg CE . Three-dimensional structure of recombinant human interferon-gamma . Science . 252 . 5006 . 698–702 . May 1991 . 1902591 . 10.1126/science.1902591 . 1991Sci...252..698E .
  15. Thiel DJ, le Du MH, Walter RL, D'Arcy A, Chène C, Fountoulakis M, Garotta G, Winkler FK, Ealick SE . Observation of an unexpected third receptor molecule in the crystal structure of human interferon-gamma receptor complex . Structure . 8 . 9 . 927–936 . September 2000 . 10986460 . 10.1016/S0969-2126(00)00184-2 . free .
  16. Hu X, Ivashkiv LB . Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases . Immunity . 31 . 4 . 539–550 . October 2009 . 19833085 . 2774226 . 10.1016/j.immuni.2009.09.002 .
  17. Sadir R, Forest E, Lortat-Jacob H . The heparan sulfate binding sequence of interferon-gamma increased the on rate of the interferon-gamma-interferon-gamma receptor complex formation . The Journal of Biological Chemistry . 273 . 18 . 10919–10925 . May 1998 . 9556569 . 10.1074/jbc.273.18.10919 . free .
  18. Vanhaverbeke C, Simorre JP, Sadir R, Gans P, Lortat-Jacob H . NMR characterization of the interaction between the C-terminal domain of interferon-gamma and heparin-derived oligosaccharides . The Biochemical Journal . 384 . Pt 1 . 93–99 . November 2004 . 15270718 . 1134092 . 10.1042/BJ20040757 .
  19. Lortat-Jacob H, Grimaud JA . Interferon-gamma binds to heparan sulfate by a cluster of amino acids located in the C-terminal part of the molecule . FEBS Letters . 280 . 1 . 152–154 . March 1991 . 1901275 . 10.1016/0014-5793(91)80225-R . 45942972 . free . 1991FEBSL.280..152L .
  20. Platanias LC . Mechanisms of type-I- and type-II-interferon-mediated signalling . Nature Reviews. Immunology . 5 . 5 . 375–386 . May 2005 . 15864272 . 10.1038/nri1604 . 1472195 . free .
  21. Schneider WM, Chevillotte MD, Rice CM . Interferon-stimulated genes: a complex web of host defenses . Annual Review of Immunology . 32 . 1 . 513–545 . 2014-03-21 . 24555472 . 4313732 . 10.1146/annurev-immunol-032713-120231 .
  22. Castro F, Cardoso AP, Gonçalves RM, Serre K, Oliveira MJ . Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion . Frontiers in Immunology . 9 . 847 . 2018 . 29780381 . 10.3389/fimmu.2018.00847 . 5945880 . free .
  23. Schroder K, Hertzog PJ, Ravasi T, Hume DA . Interferon-gamma: an overview of signals, mechanisms and functions . Journal of Leukocyte Biology . 75 . 2 . 163–189 . February 2004 . 14525967 . 10.1189/jlb.0603252 . 15862242 .
  24. Konjević GM, Vuletić AM, Mirjačić Martinović KM, Larsen AK, Jurišić VB . The role of cytokines in the regulation of NK cells in the tumor environment . Cytokine . 117 . 30–40 . May 2019 . 30784898 . 10.1016/j.cyto.2019.02.001 . 73482632 .
  25. Hoyer FF, Naxerova K, Schloss MJ, Hulsmans M, Nair AV, Dutta P, Calcagno DM, Herisson F, Anzai A, Sun Y, Wojtkiewicz G, Rohde D, Frodermann V, Vandoorne K, Courties G, Iwamoto Y, Garris CS, Williams DL, Breton S, Brown D, Whalen M, Libby P, Pittet MJ, King KR, Weissleder R, Swirski FK, Nahrendorf M . Tissue-Specific Macrophage Responses to Remote Injury Impact the Outcome of Subsequent Local Immune Challenge . Immunity . 51 . 5 . 899–914.e7 . November 2019 . 31732166 . 6892583 . 10.1016/j.immuni.2019.10.010 .
  26. Yao Y, Jeyanathan M, Haddadi S, Barra NG, Vaseghi-Shanjani M, Damjanovic D, Lai R, Afkhami S, Chen Y, Dvorkin-Gheva A, Robbins CS, Schertzer JD, Xing Z . Induction of Autonomous Memory Alveolar Macrophages Requires T Cell Help and Is Critical to Trained Immunity . Cell . 175 . 6 . 1634–1650.e17 . November 2018 . 30433869 . 10.1016/j.cell.2018.09.042 . free .
  27. Luckheeram RV, Zhou R, Verma AD, Xia B . CD4⁺T cells: differentiation and functions . Clinical & Developmental Immunology . 2012 . 925135 . 2012 . 22474485 . 3312336 . 10.1155/2012/925135 . free .
  28. Mukhopadhyay S, Farver CF, Vaszar LT, Dempsey OJ, Popper HH, Mani H, Capelozzi VL, Fukuoka J, Kerr KM, Zeren EH, Iyer VK, Tanaka T, Narde I, Nomikos A, Gumurdulu D, Arava S, Zander DS, Tazelaar HD . Causes of pulmonary granulomas: a retrospective study of 500 cases from seven countries . Journal of Clinical Pathology . 65 . 1 . 51–57 . January 2012 . 22011444 . 10.1136/jclinpath-2011-200336 . 28504428 .
  29. Wu C, Xue Y, Wang P, Lin L, Liu Q, Li N, Xu J, Cao X . IFN-γ primes macrophage activation by increasing phosphatase and tensin homolog via downregulation of miR-3473b . Journal of Immunology . 193 . 6 . 3036–3044 . September 2014 . 25092892 . 10.4049/jimmunol.1302379 . 90897269 . free .
  30. Herbst S, Schaible UE, Schneider BE . Interferon gamma activated macrophages kill mycobacteria by nitric oxide induced apoptosis . PLOS ONE . 6 . 5 . e19105 . May 2011 . 21559306 . 3085516 . 10.1371/journal.pone.0019105 . 2011PLoSO...619105H . free .
  31. Harris J, Master SS, De Haro SA, Delgado M, Roberts EA, Hope JC, Keane J, Deretic V . Th1-Th2 polarisation and autophagy in the control of intracellular mycobacteria by macrophages . Veterinary Immunology and Immunopathology . 128 . 1–3 . 37–43 . March 2009 . 19026454 . 2789833 . 10.1016/j.vetimm.2008.10.293 .
  32. Ashkar AA, Di Santo JP, Croy BA . Interferon gamma contributes to initiation of uterine vascular modification, decidual integrity, and uterine natural killer cell maturation during normal murine pregnancy . The Journal of Experimental Medicine . 192 . 2 . 259–270 . July 2000 . 10899912 . 2193246 . 10.1084/jem.192.2.259 .
  33. Micallef A, Grech N, Farrugia F, Schembri-Wismayer P, Calleja-Agius J . The role of interferons in early pregnancy . Gynecological Endocrinology . 30 . 1 . 1–6 . January 2014 . 24188446 . 10.3109/09513590.2012.743011 . 207489059 .
  34. Berkowitz RS, Hill JA, Kurtz CB, Anderson DJ . Effects of products of activated leukocytes (lymphokines and monokines) on the growth of malignant trophoblast cells in vitro . American Journal of Obstetrics and Gynecology . 158 . 1 . 199–203 . January 1988 . 2447775 . 10.1016/0002-9378(88)90810-1 .
  35. Razaghi A, Owens L, Heimann K . Review of the recombinant human interferon gamma as an immunotherapeutic: Impacts of production platforms and glycosylation . Journal of Biotechnology . 240 . 48–60 . December 2016 . 27794496 . 10.1016/j.jbiotec.2016.10.022 .
  36. Razaghi A, Tan E, Lua LH, Owens L, Karthikeyan OP, Heimann K . Is Pichia pastoris a realistic platform for industrial production of recombinant human interferon gamma? . Biologicals . 45 . 52–60 . January 2017 . 27810255 . 10.1016/j.biologicals.2016.09.015 . 28204059 .
  37. Todd PA, Goa KL . Interferon gamma-1b. A review of its pharmacology and therapeutic potential in chronic granulomatous disease . Drugs . 43 . 1 . 111–122 . January 1992 . 1372855 . 10.2165/00003495-199243010-00008 . 46986837 .
  38. Key LL, Ries WL, Rodriguiz RM, Hatcher HC . Recombinant human interferon gamma therapy for osteopetrosis . The Journal of Pediatrics . 121 . 1 . 119–124 . July 1992 . 1320672 . 10.1016/s0022-3476(05)82557-0 .
  39. Errante PR, Frazão JB, Condino-Neto A . The use of interferon-gamma therapy in chronic granulomatous disease . Recent Patents on Anti-Infective Drug Discovery . 3 . 3 . 225–230 . November 2008 . 18991804 . 10.2174/157489108786242378 .
  40. Silverman E . Drug Marketing. The line between scientific uncertainty and promotion of snake oil . BMJ . 347 . f5687 . September 2013 . 24055923 . 10.1136/bmj.f5687 . 27716008 .
  41. Web site: Statement from the Press Secretary Regarding Executive Grants of Clemency . . . January 20, 2021.
  42. Wells M, Seyer L, Schadt K, Lynch DR . IFN-γ for Friedreich ataxia: present evidence . Neurodegenerative Disease Management . 5 . 6 . 497–504 . December 2015 . 26634868 . 10.2217/nmt.15.52 .
  43. Seyer L, Greeley N, Foerster D, Strawser C, Gelbard S, Dong Y, Schadt K, Cotticelli MG, Brocht A, Farmer J, Wilson RB, Lynch DR . Open-label pilot study of interferon gamma-1b in Friedreich ataxia . Acta Neurologica Scandinavica . 132 . 1 . 7–15 . July 2015 . 25335475 . 10.1111/ane.12337 . 207014054 . free .
  44. Lynch DR, Hauser L, McCormick A, Wells M, Dong YN, McCormack S, Schadt K, Perlman S, Subramony SH, Mathews KD, Brocht A, Ball J, Perdok R, Grahn A, Vescio T, Sherman JW, Farmer JM . Randomized, double-blind, placebo-controlled study of interferon-γ 1b in Friedreich Ataxia . Annals of Clinical and Translational Neurology . 6 . 3 . 546–553 . March 2019 . 30911578 . 6414489 . 10.1002/acn3.731 .
  45. Yetkİn MF, GÜltekİn M . Efficacy and Tolerability of Interferon Gamma in Treatment of Friedreich's Ataxia: Retrospective Study . Noro Psikiyatri Arsivi . 57 . 4 . 270–273 . December 2020 . 33354116 . 7735154 . 10.29399/npa.25047 .
  46. Akhavan A, Rudikoff D . Atopic dermatitis: systemic immunosuppressive therapy . Seminars in Cutaneous Medicine and Surgery . 27 . 2 . 151–155 . June 2008 . 18620137 . 10.1016/j.sder.2008.04.004 .
  47. Schneider LC, Baz Z, Zarcone C, Zurakowski D . Long-term therapy with recombinant interferon-gamma (rIFN-gamma) for atopic dermatitis . Annals of Allergy, Asthma & Immunology . 80 . 3 . 263–268 . March 1998 . 9532976 . 10.1016/S1081-1206(10)62968-7 .
  48. Hanifin JM, Schneider LC, Leung DY, Ellis CN, Jaffe HS, Izu AE, Bucalo LR, Hirabayashi SE, Tofte SJ, Cantu-Gonzales G . Recombinant interferon gamma therapy for atopic dermatitis . Journal of the American Academy of Dermatology . 28 . 2 Pt 1 . 189–197 . February 1993 . 8432915 . 10.1016/0190-9622(93)70026-p .
  49. Brar K, Leung DY . Recent considerations in the use of recombinant interferon gamma for biological therapy of atopic dermatitis . Expert Opinion on Biological Therapy . 16 . 4 . 507–514 . 2016 . 26694988 . 4985031 . 10.1517/14712598.2016.1135898 .
  50. Kak G, Raza M, Tiwari BK . Interferon-gamma (IFN-γ): Exploring its implications in infectious diseases . Biomolecular Concepts . 9 . 1 . 64–79 . May 2018 . 29856726 . 10.1515/bmc-2018-0007 . 46922378 . free .
  51. Jorgovanovic D, Song M, Wang L, Zhang Y . Roles of IFN-γ in tumor progression and regression: a review . Biomarker Research . 8 . 1 . 49 . 2020-09-29 . 33005420 . 7526126 . 10.1186/s40364-020-00228-x . free .
  52. Casarrubios M, Provencio M, Nadal E, Insa A, del Rosario García-Campelo M, Lázaro-Quintela M, Dómine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé R, Viñolas N, Barneto Aranda I, Massuti B, Sierra-Rodero B, Martinez-Toledo C, Fernández-Miranda I, Serna-Blanco R, Romero A, Calvo V, Cruz-Bermúdez A . Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy . Journal for ImmunoTherapy of Cancer . September 2022 . 10 . 9 . e005320 . 10.1136/jitc-2022-005320. 36171009 . 9528578 . 2445/190198 . free .
  53. Ni L, Lu J . Interferon gamma in cancer immunotherapy . Cancer Medicine . 7 . 9 . 4509–4516 . September 2018 . 30039553 . 6143921 . 10.1002/cam4.1700 .
  54. Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, Yoshioka Y, Baba T, Konishi I, Mandai M . IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer . British Journal of Cancer . 112 . 9 . 1501–1509 . April 2015 . 25867264 . 4453666 . 10.1038/bjc.2015.101 .
  55. Razaghi A, Villacrés C, Jung V, Mashkour N, Butler M, Owens L, Heimann K . Improved therapeutic efficacy of mammalian expressed-recombinant interferon gamma against ovarian cancer cells . Experimental Cell Research . 359 . 1 . 20–29 . October 2017 . 28803068 . 10.1016/j.yexcr.2017.08.014 . 12800448 .
  56. Thiel DJ, le Du MH, Walter RL, D'Arcy A, Chène C, Fountoulakis M, Garotta G, Winkler FK, Ealick SE . Observation of an unexpected third receptor molecule in the crystal structure of human interferon-gamma receptor complex . Structure . 8 . 9 . 927–936 . September 2000 . 10986460 . 10.1016/S0969-2126(00)00184-2 . free .
  57. Kotenko SV, Izotova LS, Pollack BP, Mariano TM, Donnelly RJ, Muthukumaran G, Cook JR, Garotta G, Silvennoinen O, Ihle JN . Interaction between the components of the interferon gamma receptor complex . The Journal of Biological Chemistry . 270 . 36 . 20915–20921 . September 1995 . 7673114 . 10.1074/jbc.270.36.20915 . free .
  58. Leon Rodriguez DA, Carmona FD, Echeverría LE, González CI, Martin J . IL18 Gene Variants Influence the Susceptibility to Chagas Disease . PLOS Neglected Tropical Diseases . 10 . 3 . e0004583 . March 2016 . 27027876 . 4814063 . 10.1371/journal.pntd.0004583 . free .
  59. Trznadel-Grodzka E, Błaszkowski M, Rotsztejn H . Investigations of seborrheic dermatitis. Part I. The role of selected cytokines in the pathogenesis of seborrheic dermatitis . Postepy Higieny I Medycyny Doswiadczalnej . 66 . 843–847 . November 2012 . 23175340 . 10.5604/17322693.1019642 . free .
  60. Bigley NJ . Complexity of Interferon-γ Interactions with HSV-1 . Frontiers in Immunology . 5 . 15 . 2014-02-06 . 24567732 . 3915238 . 10.3389/fimmu.2014.00015 . free .
  61. Sodeik B, Ebersold MW, Helenius A . Microtubule-mediated transport of incoming herpes simplex virus 1 capsids to the nucleus . The Journal of Cell Biology . 136 . 5 . 1007–1021 . March 1997 . 9060466 . 2132479 . 10.1083/jcb.136.5.1007 .
  62. Huang WY, Su YH, Yao HW, Ling P, Tung YY, Chen SH, Wang X, Chen SH . Beta interferon plus gamma interferon efficiently reduces acyclovir-resistant herpes simplex virus infection in mice in a T-cell-independent manner . The Journal of General Virology . 91 . Pt 3 . 591–598 . March 2010 . 19906941 . 10.1099/vir.0.016964-0 . free .
  63. Sainz B, Halford WP . Alpha/Beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1 . Journal of Virology . 76 . 22 . 11541–11550 . November 2002 . 12388715 . 136787 . 10.1128/JVI.76.22.11541-11550.2002 .
  64. Khanna KM, Lepisto AJ, Decman V, Hendricks RL . Immune control of herpes simplex virus during latency . Current Opinion in Immunology . 16 . 4 . 463–469 . August 2004 . 15245740 . 10.1016/j.coi.2004.05.003 .
  65. Rottenberg ME, Gigliotti-Rothfuchs A, Wigzell H . The role of IFN-gamma in the outcome of chlamydial infection . Current Opinion in Immunology . 14 . 4 . 444–451 . August 2002 . 12088678 . 10.1016/s0952-7915(02)00361-8 .
  66. Taylor MW, Feng GS . Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism . FASEB Journal . 5 . 11 . 2516–2522 . August 1991 . 1907934 . 10.1096/fasebj.5.11.1907934 . free . 25298471 .
  67. Bernstein-Hanley I, Coers J, Balsara ZR, Taylor GA, Starnbach MN, Dietrich WF . The p47 GTPases Igtp and Irgb10 map to the Chlamydia trachomatis susceptibility locus Ctrq-3 and mediate cellular resistance in mice . Proceedings of the National Academy of Sciences of the United States of America . 103 . 38 . 14092–14097 . September 2006 . 16959883 . 1599917 . 10.1073/pnas.0603338103 . 2006PNAS..10314092B . free .
  68. Nelson DE, Virok DP, Wood H, Roshick C, Johnson RM, Whitmire WM, Crane DD, Steele-Mortimer O, Kari L, McClarty G, Caldwell HD . Chlamydial IFN-gamma immune evasion is linked to host infection tropism . Proceedings of the National Academy of Sciences of the United States of America . 102 . 30 . 10658–10663 . July 2005 . 16020528 . 1180788 . 10.1073/pnas.0504198102 . 2005PNAS..10210658N . free .
  69. Ben-Asouli Y, Banai Y, Pel-Or Y, Shir A, Kaempfer R . Human interferon-gamma mRNA autoregulates its translation through a pseudoknot that activates the interferon-inducible protein kinase PKR . Cell . 108 . 2 . 221–232 . January 2002 . 11832212 . 10.1016/S0092-8674(02)00616-5 . 14722737 . free .
  70. Asirvatham AJ, Gregorie CJ, Hu Z, Magner WJ, Tomasi TB . MicroRNA targets in immune genes and the Dicer/Argonaute and ARE machinery components . Molecular Immunology . 45 . 7 . 1995–2006 . April 2008 . 18061676 . 2678893 . 10.1016/j.molimm.2007.10.035 .
  71. Chang CH, Curtis JD, Maggi LB, Faubert B, Villarino AV, O'Sullivan D, Huang SC, van der Windt GJ, Blagih J, Qiu J, Weber JD, Pearce EJ, Jones RG, Pearce EL . Posttranscriptional control of T cell effector function by aerobic glycolysis . Cell . 153 . 6 . 1239–1251 . June 2013 . 23746840 . 3804311 . 10.1016/j.cell.2013.05.016 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Interferon gamma".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.